Table 1.
Clinical characteristics of patients.
| Characteristic | GSE32646 (n = 115) | GSE20271 (n = 74) | GSE20194 (n = 207) | GSE25055 (n = 227) | GSE41998 (n = 121) |
|---|---|---|---|---|---|
| Age (years) | |||||
| <65 | 102 | 61 | 172 | 197 | 113 |
| ≥65 | 13 | 13 | 35 | 30 | 8 |
| Tumor stage | |||||
| T0 | 0 | 1 | 3 | 2 | 0 |
| T1 | 5 | 3 | 20 | 19 | 2 |
| T2 | 87 | 34 | 119 | 131 | 79 |
| T3 | 18 | 18 | 31 | 35 | 40 |
| T4 | 5 | 18 | 34 | 40 | 0 |
| Lymph node status | |||||
| Positive | 83 | 46 | 139 | 165 | NA |
| Negative | 32 | 28 | 68 | 62 | NA |
| Histological grade | |||||
| 1 | 16 | 9 | 10 | 13 | NA |
| 2 | 78 | 25 | 82 | 92 | NA |
| 3 | 21 | 27 | 115 | 122 | NA |
| NA | 13 | ||||
| ER status | |||||
| Positive | 71 | 41 | 125 | 131 | 45 |
| Negative | 44 | 33 | 82 | 96 | 76 |
| PR status | |||||
| Positive | 45 | 36 | 90 | 102 | 46 |
| Negative | 70 | 38 | 117 | 125 | 75 |
| HER2 status | |||||
| Positive | 34 | 14 | 45 | 0 | 9 |
| Negative | 81 | 60 | 162 | 227 | 112 |
| Neoadjuvant therapy | |||||
| Weekly T×12+FAC×4 | 115 | 74 | 119 | 227 | 0 |
| 3-weekly T×4+FAC×4 | 0 | 0 | 88 | 0 | 0 |
| Weekly T×12+AC×4 | 0 | 0 | 0 | 0 | 121 |
| Pathologic response | |||||
| RD | 88 | 57 | 161 | 184 | 87 |
| pCR | 27 | 17 | 46 | 43 | 34 |
ER, Estrogen Receptor; PR, Progesterone Receptor; HER2, Human Epidermal Growth Factor Receptor 2; RD, Residual Disease; pCR, Pathologic Complete Response; NA, Not Available.